Compare QNBC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNBC | TRDA |
|---|---|---|
| Founded | 1877 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.3M | 275.3M |
| IPO Year | 1996 | 2021 |
| Metric | QNBC | TRDA |
|---|---|---|
| Price | $46.12 | $4.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 18.7K | ★ 290.0K |
| Earning Date | 10-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 21.15 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | ★ $25,421,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $87.90 |
| P/E Ratio | $34.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.75 | $4.83 |
| 52 Week High | $46.60 | $16.45 |
| Indicator | QNBC | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 58.88 | 22.26 |
| Support Level | $45.00 | N/A |
| Resistance Level | $46.60 | $7.89 |
| Average True Range (ATR) | 0.47 | 0.38 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 65.63 | 1.34 |
QNB Corp is a bank holding company based in the United States. It operates through its wholly-owned subsidiary, which engages in the general commercial banking business and offers a full range of banking services to its customers. Its business activities involve attracting deposits and using funds in making commercial loans, residential mortgage loans, consumer loans, and purchasing investment securities. The loan portfolio includes commercial loans, such as commercial and industrial, construction, and loans secured by commercial real estate and residential real estate, and retail loans, including home equity loans and lines, and consumer loans. It generates revenue from net interest income.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.